RxDoctor Payments Data

Kayla Lafaver, DO

Internal Medicine · Columbia, SCNPI 1598256307

Payments from drug & device makers

$595in general payments, 2019–2025

Across 33 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$123
  • Lilly USA, LLC$109
  • Bayer$96
  • AbbVie$66
  • Abbott$61
  • Novartis$45
  • plus $95 from 5 others

What the payments were for

  • Food & beverage$595100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$595 in reported general payments places this provider in the 60th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$183,994
Medicare patients
221
Services billed
2,403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$102,976
JardianceEmpagliflozin68$88,210
MounjaroTirzepatide34$65,638
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$43,275
EliquisApixaban32$41,436
JanuviaSitagliptin Phosphate26$28,386
TrulicityDulaglutide12$25,973
Synjardy XrEmpagliflozin/Metformin Hcl18$20,190
Repatha SureclickEvolocumab20$11,862
XareltoRivaroxaban16$10,881
Amlodipine-ValsartanAmlodipine Besylate/Valsartan75$4,736
Novolog FlexpenInsulin Aspart23$3,420
SymbicortBudesonide/Formoterol Fumarate14$3,097
Duloxetine Hcl101$3,012
Icosapent Ethyl20$2,881

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$16$108,40186 claims
Novo NordiskOzempic$123$102,97668 claims
Lilly USA, LLCMounjaro, Trulicity$109$91,61146 claims
GSKTrelegy Ellipta$16$43,27567 claims
PfizerEliquis$30$41,43632 claims
Johnson & JohnsonXarelto$15$10,88116 claims
AstraZenecaSymbicort$19$3,09714 claims
AbbVieSynthroid$66$1,29222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →